Acute Variceal Bleeding
Conditions
Brief summary
The study is single centered; prospective, parallel arm randomized controlled trial.The patients will be who presented to Institute of Liver & Biliary Sciences with esophageal variceal bleeding or develop esophageal bleeding during hospital stay. All patients will be managed with continuous non-invasive cardiac and hemodynamic monitoring including cardiac rhythm, pulse rate, blood pressure, and oxygen saturation. Hemoglobin (Hb) will checked every 6 h for the initial 48 h and then every 12 h till discharge. Likewise, serum creatinine will checked daily. Packed red blood cells will be transfused to maintain target Hb of ⩾8 g/dl. Patients will be started on IV Proton Pump Inhibitor, with bolus dose of terlipressin (2mg) followed by Endoscopic variceal ligation. All patients will received prophylactic antibiotics; antibiotics will be stopped if there will no other indication to continue. After confirmation of EVB (Esophageal Variceal Bleeding) and successful initial hemostasis with emergency EVBL (Endoscopic Variceal Band ligation), patients will be randomly assigned into Group -A (Bolus terlipressin at 2mg every 4hourly) and Group-B (Continuous infusion of terlipressin @ 4mg/24hour initially) therapy for esophageal varices . They will then undergo HVPG (Hepatic Venous Pressure Gradient) measurement at baseline, 12hours and 24hours. Patient in continuous group will titrate dose. accordingly to HVPG (Hepatic Venous Pressure Gradient) measurement at 12 and 24 hours. At 24 hours patient will be directed to receive either TIPS (Transjugular Intrahepatic Portosystemic Shunt) or will continue Terlipressin for 48 hours.
Interventions
DRUGTerlipressin
Sponsors
Institute of Liver and Biliary Sciences, India
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Any patient with only acute esophageal variceal bleeding (as defined by Asian pacific Association for the study of Liver Disease) * Informed consent to participate in the study * Age 18 to 70 years
Exclusion criteria
* Pregnant and lactation * Prior treatment with any vasoactive drugs * Significant heart or respiratory failure * Peripheral arteriopathy clinically significant * Previous heart stroke or significant alteration of the Electrocardiogram * Hemodynamically unstable * Refusal to participate in the study * Hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of HVPG (hepatic venous pressure gradient) at 24 hours >10% | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| Terlipressin related complications in both groups | 72 hours |
| Rebleed within 42 days | 42 days |
| number of blood transfusion requirement at 5 days | 5 days |
| Death in both groups | 42 days |
| Incidence of post bleed acute kidney injury within 5 days | 5 days |
| Incidence of post EVL(endoscopic band ligation) ulcer bleed within 5 days | 5 days |
| Incidence of ischaemic hepatitis within 5 days | 5 days |
Countries
India
Outcome results
None listed